Transport Corporation of India

Bernstein believes Donald Trump’s proposed tariffs of up to 200% on Indian generic medicines are more likely to be a negotiating tactic than a lasting policy shift. The brokerage says large Indian pharmaceutical companies remain well positioned due to their existing US manufacturing footprint, operational flexibility and the high cost of producing generic medicines in the US.